GENinCode UK Ltd. (GB:GENI) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
GENinCode UK Ltd. has published a study highlighting the impact of lifestyle and genetic factors on coronary heart disease, showcasing that individuals with high polygenic risk can significantly reduce their risk through lifestyle changes. The company’s CARDIO inCode-Score® is gaining adoption in leading U.S. healthcare institutions, contributing to its projected revenue growth of up to 39% for 2024. GENinCode continues to expand its market presence, marking its first U.S. revenues and strengthening its position in the cardiovascular disease prevention sector.
For further insights into GB:GENI stock, check out TipRanks’ Stock Analysis page.
